[February 23, 2015]

Fluoresentric XCRTM Wins Top Spot at Molecular Diagnostic Tri-Conference

Fluoresentric, Inc. today announced garnering of the coveted "Most Promising Company" First Place award at this month's Molecular Med Tri-Con 2015. The company won in competition among presenters pitching their company's value proposition to a panel of industry leaders at the Inaugural Swimming with the Sharks competition. Presenters were judged on clinical utility, investor readiness, and healthcare impact.

"The inaugural Swimming with the Sharks at Tri-Con featured 12 fine life science start-ups from an initial field of about two dozen," stated Chris Heid, vice president for Humanzyme and Tri-Con Swimming with the Sharks judge. "Fluoresentric emerged as the unanimous first choice and clear winner from the five promising finalist companies."

Fluoresentric outlined for judges its disruptive XCR™ technology. XCR™ combines the best of Polymerase Chain Reaction (PCR (News - Alert)) and isothermal methods with none of their limitations. It is as uch as 10-fold faster than PCR and has no primer dimer, low cost reagents, low cost portable instrumentation, high multi-plex, resistance to PCR inhibitors with streamlined sample prep.

"We feel honored to be named Tri-Con Most Promising Company among such a promising group of competitors," states William Olson (News - Alert), Fluoresentric CEO. "Judges recognized that XCR™ is positioned to improve molecular diagnostics in the lab, as well as at point-of-care. We are so happy to represent Tri-Con and the industry as we all work towards better, more affordable healthcare."

The current standard for nucleic acid amplification requires 40 to 60 minutes, an unacceptable time for several critical testing areas, particularly at the Point of Care, where testing must be completed in less than 20 minutes to get a clinically actionable result. As a new approach to nucleic acid amplification testing (NAAT), XCR™ amplification and detection occurs in ~5 minutes with both DNA and RNA target nucleic acids. It eliminates amplification artifacts (e.g., primer-dimer) while dramatically reducing turnaround time, delivering a clinical result without compromise.

Sponsors for this inaugural event include Abbott Molecular, Elsevier, IBM (News - Alert), The Jackson Laboratory, Leica Biosystems, NanoString Technologies, Silicon Biosystems, and Singulex, among others.

About Fluoresentric, Inc.

Fluoresentric Inc. is a start-up chemistry company positioned to monetize its XCR™ technology portfolio globally. Initially started as a custom PCR assay Design Company recruited by Roche to support their LightCycler^® thermalcycler, the company has designed over 1,000 PCR assays. Fluoresentric scientists are internationally recognized experts in the field of Real Time Polymerase Chain Reaction (PCR). The company's XCR™ technology is positioned to dramatically trim test times, reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing at Point of Care.

*LightCycler^® is a registered trademark of Roche.

[ Back To TMCnet.com's Homepage ]